Reaching a Tipping Point for Neurorehabilitation Research: Obstacles and Opportunities in Trial Design, Description, and Pooled Analysis.
William M SavageNoam Y HarelPublished in: Neurorehabilitation and neural repair (2022)
The record-breaking pace of COVID-19 vaccine development and implementation depended heavily on collaboration among academic, government, and commercial stakeholders, especially through data-sharing and robust multicenter trials. Collaborative efforts have not been as fruitful in fields such as neurorehabilitation, where non-pharmacological interventions play a much larger role. Barriers to translating scientific advancements into clinical practice in neurorehabilitation include pervasively small study sizes, exacerbated by limited funding for non-pharmacological multicenter clinical trials; difficulty standardizing-and adequately describing-non-pharmacological interventions; and a lack of incentives for individual patient-level data-sharing. These barriers prevent reliable meta-analysis of non-pharmacological clinical studies in neurorehabilitation. This point-of-view will highlight these challenges as well as suggest practical steps that may be taken to improve the neurorehabilitation pipeline between evidence and implementation.
Keyphrases
- quality improvement
- clinical trial
- primary care
- clinical practice
- healthcare
- physical activity
- electronic health record
- sars cov
- coronavirus disease
- social media
- phase ii
- health information
- cross sectional
- double blind
- phase iii
- case report
- randomized controlled trial
- study protocol
- machine learning
- data analysis
- hiv testing